Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial.
10.1007/s11655-022-3467-1
- Author:
Sheng-Jing LIU
1
;
Ying-Jun DENG
1
;
Yin ZENG
2
;
Ming ZHAO
3
;
Jun GUO
1
;
Qing-He GAO
4
Author Information
1. Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
2. Department of Andrology, Beijing Chinese Medicine Hospital Affiliated to Capital Medical University, Beijing, 100010, China.
3. Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
4. Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China. gaoqinghe1949@126.com.
- Publication Type:Randomized Controlled Trial
- Keywords:
Chinese medicine;
Guihuang Formula;
dampness-heat and blood stasis syndrome;
randomized controlled trial;
type III prostatitis
- MeSH:
Chronic Disease;
Hot Temperature;
Humans;
Lecithins;
Male;
Pain;
Prostatitis/drug therapy*;
Quality of Life;
Tamsulosin
- From:
Chinese journal of integrative medicine
2022;28(10):879-884
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To observe the efficacy and safety of Guihuang Formula (GHF) in treating patients with type III prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis.
METHODS:Sixty-six patients diagnosed with type III prostatitis with dampness-heat and blood stasis syndrome were randomly divided into the treatment group (GHF) and the control group (tamsulosin) using a random number table, with 33 cases each group. The treatment group received GHF twice a day, and the control group received tamsulosin 0.2 mg once daily before bedtime. Patients in both groups received treatment for 6 weeks and was followed up for 2 weeks. The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score, Chinese Medicine Symptoms Score (CMSS), expressed prostatic secretions (EPS) and adverse events (AEs).
RESULTS:After treatment, the NIH-CPSI total score and domain scores of pain discomfort, urination and quality of life decreased significantly from the baseline in both groups (P<0.05). The CMSS score decreased in both groups (P<0.05). The WBC count decreased and lecithin body count increased in both groups (P<0.05). GHF showed a more obvious advantage in reducing the pain discomfort and quality of life domain scores of NIH-CPSI, reducing the CMSS score, increasing the improvement rate of the WBC and lecithin body counts, compared with the control group (P<0.05). There were no significant differences in decreasing urination domain score of NIH-CPSI between two groups (P>0.05). In addition, no serious AEs were observed.
CONCLUSION:GHF is effective in treating type III prostatitis patients with dampness-heat and blood stasis syndrome without serious AEs. (Registration No. ChiCTR1900026966).
